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IMPORTANCE Chronic cerebrospinal venous insufficiency (CCSVI) is characterized by
restricted venous outflow from the brain and spinal cord. Whether this condition is associated
with multiple sclerosis (MS) and whether venous percutaneous transluminal angioplasty
(PTA) is beneficial in persons with MS and CCSVI is controversial.
OBJECTIVE To determine the efficacy and safety of venous PTA in patients withMS and CCSVI.
DESIGN, SETTING, AND PARTICIPANTS We analyzed 177 patients with relapsing-remittingMS;
62 were ineligible, including 47 (26.6%) who did not have CCSVI on color Doppler
ultrasonography screening. A total of 115 patients were recruited in the study timeframe. All
patients underwent a randomized, double-blind, sham-controlled, parallel-group trial in 6MS
centers in Italy. The trial began in August 2012 and concluded in March 2016; data were
analyzed from April 2016 to September 2016. The analysis was intention to treat.
INTERVENTIONS Patients were randomly allocated (2:1) to either venous PTA or catheter
venography without venous angioplasty (sham).
MAIN OUTCOMES ANDMEASURES Two primary end points were assessed at 12months:
(1) a composite functional measure (ie, walking control, balance, manual dexterity, postvoid
residual urine volume, and visual acuity) and (2) a measure of new combined brain lesions on
magnetic resonance imaging, including the proportion of lesion-free patients. Combined
lesions included T1 gadolinium-enhancing lesions plus new or enlarged T2 lesions.
RESULTS Of the included 115 patients with relapsing-remitting MS, 76 were allocated to the
PTA group (45 female [59%]; mean [SD] age, 40.0 [10.3] years) and 39 to the sham group
(29 female [74%]; mean [SD] age, 37.5 [10.6] years); 112 (97.4%) completed follow-up.
No serious adverse events occurred. Flow restoration was achieved in 38 of 71 patients (54%)
in the PTA group. The functional composite measure did not differ between the PTA and
sham groups (41.7% vs 48.7%; odds ratio, 0.75; 95% CI, 0.34-1.68; P = .49). Themean (SD)
number of combined lesions onmagnetic resonance imaging at 6 to 12 months were 0.47
(1.19) in the PTA group vs 1.27 (2.65) in the sham group (mean ratio, 0.37; 95% CI, 0.15-0.91;
P = .03: adjusted P = .09) and were 1.40 (4.21) in the PTA group vs 1.95 (3.73) in the sham
group at 0 to 12 months (mean ratio, 0.72; 95% CI, 0.32-1.63; P = .45; adjusted P = .45). At
follow-up after 6 to 12 months, 58 of 70 patients (83%) in the PTA group and 22 of 33 (67%)
in the sham group were free of new lesions onmagnetic resonance imaging (odds ratio, 2.64;
95% CI, 1.11-6.28; P = .03; adjusted P = .09). At 0 to 12 months, 46 of 73 patients (63.0%) in
the PTA group and 18 of 37 (49%) in the sham group were free of new lesions onmagnetic
resonance imaging (odds ratio, 1.80; 95% CI, 0.81-4.01; P = .15; adjusted P = .30).
CONCLUSION AND RELEVANCE Venous PTA has proven to be a safe but largely ineffective
technique; the treatment cannot be recommended in patients with MS.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01371760
JAMA Neurol. 2018;75(1):35-43. doi:10.1001/jamaneurol.2017.3825
Published online November 18, 2017.
Editorial page 15
Supplemental content
Author Affiliations:Author
affiliations are listed at the end of this
article.
Group Information: Themembers of
the Brave Dreams Research Group
are listed at the end of the article.
Corresponding Author: Paolo
Zamboni, MD, Translational Surgery
and Vascular Diseases Centre,
University of Ferrara Hospital, Via
AldoMoro 8, 44124 Cona, Ferrara,
Italy (paolozamboni@icloud.com).
Research
JAMANeurology | Original Investigation
(Reprinted) 35
Downloaded From:  by a Universita degli di Milano User  on 03/07/2018
W hen intraluminal defects, compression, orhypopla-sia are identified in the internal jugular or azygosveins, the condition is known as chronic cerebro-
spinal venous insufficiency (CCSVI).1,2 An Italian open-label
study3 published in 2009 including 65 patientswithmultiple
sclerosis (MS) foundanassociationbetweenMSandCCSVI.The
study also found that venous percutaneous transluminal
angioplasty (PTA) was associated with an improved Multiple
Sclerosis Functional Composite (MSFC) score at 1 year in pa-
tientswith relapsing-remittingMS (RRMS) and a reduction in
theproportionof thosewithgadolinium-enhancing lesionson
brain magnetic resonance imaging (MRI). This preliminary
studyattracted considerablemedia attention in Italy andelse-
where; media-based groups formed to promote the treat-
ment, and some called to make it freely available.4
Subsequent to the initial reports by Zamboni et al,3 preva-
lence studies of CCSVI in MS have reported conflicting
results. A small 2012 case-control study5 further assessed the
potential of venous PTA to benefit patientswithMS.One year
after venous PTA, the study found that functional score was
improved compared with baseline, and the authors sug-
gested that a double-blind randomized trial was justified.5
Both theNational Institute for Health andCare Excellence
and the ItalianMinistry of Health have urged that randomized
clinical trials beconducted toassess theefficacyofvenousPTA
forCCSVI inMS.6,7 In response to these calls and topublicpres-
sure, the Directorate-General for Health and Welfare of the
Italian Region of Emilia Romagna funded the Brain Venous
Drainage Exploited Against Multiple Sclerosis (Brave Dreams)
trial to investigate the efficacy and safety of venous PTA in
patientswithMS andCCSVI.We report the results of that trial.
Methods
Study Design
TheBraveDreamstrialwasamulticenter, randomized,double-
blind, sham-controlled, parallel-group trial to evaluate the ef-
ficacy and safetyof venousPTA inpatientswithMSandCCSVI
in extracranial or extravertebral veins. The study was con-
ducted at 6 MS centers in Italy and their associated color
Doppler ultrasonography (ECD) and angiography units, all of
whichwere accredited by the ItalianNational Health Service.
TheBraveDreamssteeringcommitteeappointedanEndPoints
Commission, which issued a detailed operationsmanual and
trained trial physicians (whoassessedprimary functional out-
comes, operated the ECD equipment, and performed cath-
etervenographywithoutvenousangioplastyandvenousPTA).
After training, thecommission issuedanaccreditation thatwas
necessary forphysicians toparticipate in the trial. Studymoni-
toring was delegated to the companyMedical Trials Analysis
Italy in Ferrara, Italy. A trial data coordinating center was
established to oversee data collection and quality and to
perform the statistical analyses. The study adhered to the
Helsinki Declaration and the International Council for
Harmonisation of Technical Requirements for Pharmaceuti-
cals forHumanUseGoodClinical Practice guidelines andwas
approved by the ethical committee of the University of
Ferrara Hospital and subsequently by the ethical committees
of the other participating centers. The trial protocol has been
published.8 The trial protocol can be found in Supplement 1.
All participants provided written informed consent.
Participants
Patients were recruited at the participating centers. Eligibil-
ity criteria included age 18 to 65 years; a diagnosis of RRMS,
according to the 2005McDonald criteria9; a diagnosis of sec-
ondary progressive MS, according to Lublin and Reingold10;
care provided by the recruiting center for at least 2 years; at
least 1 relapse inRRMSinthe2yearsprior toenrollment;abase-
lineExpandedDisability Status Scale (EDSS) score of 2 to 5.511;
a disease duration of 15 years or less at baseline; stable neu-
rological conditionwithout relapse for at least 30 days before
baseline; CCSVI, as determined by ECD examination carried
out in accordancewith a screening protocol12; andnot receiv-
ing MS-specific treatment, immunomodulating, or immuno-
suppressive therapy without changes for at least 6 months
up to baseline. Patients were ineligible if they had previous
venous PTA or had received fingolimod therapy, cladribine
therapy, laquinimod therapy, botulinum toxin therapy, infu-
sion pump or neurostimulator implantation, or had partici-
pated inanyclinical trialwithin3monthsofbaseline.Thecom-
plete list of exclusion criteria was published previously.8
Randomization and Blinding
The data coordinating center set up an internet-based com-
puterized central randomizationprotocol stratifiedbypartici-
pating center with variable length blocks, which assigned pa-
tients to the PTA or sham group in a 2:1 ratio. Treatment
assignment wasmade known to the treating surgeon (via the
electronic case report form) only on the day of the operation.
Patients, all other study investigators, andoperating roomand
hospital personnel were blinded to assignment.
To maintain patient blinding, surgeons were trained to
deliver a catheter venography intervention that simulated
venous PTA.8 This involved sudden acceleration of the cath-
eter as it passed through the internal jugularvein togetherwith
a comment from the radiologist suggesting that venous PTA
had been performed.
Key Points
Question What is the efficacy of venous percutaneous
transluminal angioplasty (PTA) for chronic cerebrospinal venous
insufficiency in patients with multiple sclerosis?
Findings In the Brave Dreams trial, which included 115 patients
with relapsing-remitting multiple sclerosis, venous PTA did not
increase the proportion of patients who improved functionally nor
did it reduce themean number of new combined brain lesions on
magnetic resonance imaging at 12 months. However, there was a
tendency for more patients to become free of new lesions after
venous PTAmainly because of a reduction in new lesions
appearing 6 to 12 months after randomization.
Meaning Venous PTA cannot be recommended for patients with
relapsing-remitting multiple sclerosis.
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Procedures
Participants underwent catheter venography without ve-
nousangioplastyof theazygos and internal jugular veins,with
percutaneous access via the left femoral vein. The presence
and locationofCCSVIwas assessedas reportedelsewhere.2,3,5
If venography was positive for CCSVI, participants random-
ized to the PTA group received venous PTAduring the venog-
raphy session. If CCSVIwas absent, those assigned to the PTA
group received catheter venography without venous angio-
plasty. Those allocated to the sham group received catheter
venography without venous angioplasty. These procedures
were performed via day surgery. Overnight hospital stay was
never required in this trial. All patients received prophylactic
low-molecular-weightheparinduring the3subsequentweeks.
Outcomes
There were 2 primary end points at 12 months: a functional
end point and an MRI end point.
Functional End Point
Inviewofthepsychometric limitationsoftheEDSSandtheMSFC
scores,13,14 thesteeringcommitteedecidedtouseanewprimary
composite endpoint based on a range of the functional impair-
mentscommonlyexperiencedbypatientswithMS.Thiscompos-
ite includedwalkingcontrol,balance,manualdexterity,postvoid
residual urine volume, and visual acuity (eMethods in
Supplement2).Statisticallysignificantchangeswereadoptedfor
defining changes inwalking control, balance, andmanual dex-
terity; aminimal real differencewas used for postvoid residual
urine volume and visual acuity.15 Based on the changes found,
each index was considered improved, stable, or worsened.
Patientswereclassifiedas(1) improved,whichindicatedimprove-
ment in 1ormore functions andstability in the remaining func-
tions, (2)worsened,whichindicatedworseningof1ormorefunc-
tionsandstability innonworsening functions, (3)mixed,which
indicated presence of improved and worsened functions, or
(4)stable,whichindicatednochangeinanyfunction.Evaluations
wereperformedbyoperators (2perparticipatingcenter)atbase-
line,within15daysofvenography,and3,6,and12months later.
Only results at 12monthswere used in analyses. To ensure the
reliabilityof the functionalmeasurements, theEndPointsCom-
missionmade 1 or 2 visits to each site tomonitor the functional
assessments.Assessorswere required tomakevideorecordings
of thewalkingcontrolandmanualdexterity tests in10%ormore
of patients and to send them to the commission for inspection.
If apatienthada transient impairment thatblockedperfor-
mance of 1 ormore functional tests, thesewere not performed
until thenext follow-up. Intheeventofaclinical relapse,all tests
weredeferred.Asperstudyprotocol,thefinalroundoftestscould
take place up to 15months after venography.
Magnetic Resonance Imaging End Point
Scans were acquired at baseline and at 6 and 12 months after
venography. The primary MRI end point was the number of
new combined cerebral lesions at 12 months compared with
baseline. New combined lesions included (1) new lesions on
T2-weighted images, (2)preexisting lesionsenlargedbygreater
than 30% on T2-weighted images, and (3) gadolinium-
enhancing lesions in T1-weighted images of preexisting
lesions.AnadditionalMRI endpointwas theproportionofpa-
tients free of new lesions. Before starting the study, each cen-
ter acquired a set ofMRI scans of a single individual on2 sepa-
rate occasions. The scans were assessed by the Department
ofNeurosciences at theUniversity of Florence for imagequal-
ity, repositioning accuracy, and signal-to-noise ratio to check
that quality was sufficient. At each center, MRIs were always
performed with the same device (at least 1.5 T) and with the
same protocol. The scans were assessed by an experienced
specialist blinded to treatment assignment.
Secondary Outcomes
Secondary outcomes at 12 months were the proportion of
patients with CCSVI diagnosed by ECD but not confirmed by
venography,annualizedrelapserate, change inEDSSscore,pro-
portion of patients with relapses, and proportion of patients
whohadvenous PTAwith restored flowonECDat 12months.
Safety
The types and grade of adverse events are reported according
to the Good Clinical Practice guidelines. Stopping rules in-
cluded serious adverse events and/or a false-positive rate for
CCSVI on ECD exceeding 10%.8
Statistical Analysis
To achieve a 90% power (SD = 7.6) to detect a hypothesized
2.1 fewer activeMRI lesions in the PTA group (3.9 vs 6.0), 423
patientswithRRMSwereneeded.Thisnumberofpatientswas
also sufficient (92%power) todetect ahypothesized 15%more
patients in the PTA group than the sham group improving on
the functional end point (α = .05; 2-sided test on propor-
tions). Patients in the sham groupwere themselves expected
to improve by 15% over the year of follow-up. Because both
primary end points were used to characterize treatment ben-
efit, each null hypothesis had to be rejected at the same sig-
nificance level (α = .05),withmultiplicity adjustment only for
the MRI end point, since this had 2 parameters (mean lesion
number and proportion of lesion-free patients).16
Becauseof lowenrollment (6patientspermonthbyNovem-
ber2013), theprotocolwasamended inFebruary2014; 300pa-
tientswithRRMS(200inPTAgroupand100inshamgroup)were
requiredtoreveal thesamehypothesizeddifferences inMRIand
functionalendpoints,withpowersof80%and84%,respectively.
ThestudyclosedinDecember2014becauseofslowrecruitment,
with115patientswithRRMSrecruited(38.3%ofamendedtarget).
The initial power calculation for patients with secondary
progressive MS indicated that 222 patients were needed.8
Recruitment was stopped in February 2014, with only 15 pa-
tients recruited.Stoppingdecisionswere takenwithoutknowl-
edge of outcomes or treatment allocations.
For descriptive purposes,we calculated percentage,mean
(SD),andmedian(interquartile range),asappropriate.Themain
analysiswas intention to treat.TheeffectofPTAvsshamonthe
composite functional endpointwasassessedbycomparing the
proportions of improved patients at 1 year in the 2 groups, and
the significanceofdifferences inproportionwasassessedbyχ2
test.TheeffectofPTAvsshamontheMRIendpointwasassessed
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byanegativebinomialmodel that compared themeannumber
ofMRIlesions inthe2groupsat1year.Theproportionofpatients
whowere freeofnewbrain lesionsonMRIwerecomparedbyχ2
test. Variables thatwere unbalanced at baselinewere adjusted
forusinga logisticmodelonthefunctionalendpointandanega-
tive binomialmodel onmean number ofMRI lesions.
Relapse rates (secondary end point) in the 2 groups were
compared assuming a Poisson distribution of events. Differ-
ences in EDSS scores at 1 year were compared by analysis of
covariance testing,with adjustment for baseline scores.When
analyzing components of the functional and MRI end points
(including findings at 0 to 6 and 6 to 12months), we adjusted
for multiplicity using the Hommel method,17 since it is rea-
sonable to assume that variables involved couldbedirectly re-
lated (reportedasadjustedPvalue).All testswere2-tailed,with
the significance level set at P < .05. Analyseswere performed
with SASversion9.3 (SAS Institute) andRversion3.2 (RFoun-
dation for Statistical Computing).
Results
TheFigure shows the study flowchart for patientswith RRMS.
A total of 177 were assessed for eligibility, and 62 were ineli-
gible, including 47 (26.6%) who did not have CCSVI on ECD
screening. One hundred fifteen patientswere eligible and ran-
domly assigned to the PTA group (n = 76) or the sham group
(n = 39),which included catheter venographywithout venous
angioplasty, between August 7, 2012, and December 15, 2014.
The2groupsweresimilar forbaselinecharacteristicsexcept that
patients in the sham group had more women and longer dis-
ease duration (Table 1). No serious adverse events attributable
to catheter venographyor venous PTAoccurred, but 2 adverse
events (1.7%) did occur: 1 vagal reaction and 1 episode of tran-
sientneckpain.A total of 112 of 115patients (97.4%) completed
the 12-month follow-up, with similar proportions completing
inthe2groups.eFigure1 inSupplement2showsthestudyflow-
chart for patients with secondary progressiveMS.
Primary End Points
Functional end point results were available for 109 patients
with RRMS (Table 2). A total of 30 of 73 patients (41%) in the
PTA group and 18 of 37 (49%) in the sham group improved on
Figure. Study Flowchart for PatientsWith Relapsing-Remitting
Multiple Sclerosis
177 Patients with relapsing-remitting
multiple sclerosis assessed for eligibility
115 Patients enrolled
115 Patients randomized
76 Patients assigned to venous
percutaneous transluminal
angioplasty
74 Patients completed protocola
2 Withdrew informed
consent
72 Patients analyzed for combined
clinical end point
73 Patients analyzed for MRI
end point
39 Patients assigned to catheter
venography without venous
angioplasty
38 Patients completed protocol
1 Lost to follow-up
37 Patients analyzed for combined
clinical end point
37 Patients analyzed for MRI
end point
62 Excluded
Screening phase 1
Screening phase 2
3 Withdrew informed consent
2 Were ineligible
47 Had no CCSVI on color
Doppler ultrasonography
Were ineligible
Withdrew informed consent
5
5
a Includes 2 patients who received the sham treatment; one patient was
included bymistake and the other was included because chronic cerebrospinal
venous insufficiency was not confirmed on venography. MRI indicates
magnetic resonance imaging.
Table 1. Baseline Characteristics of Recruited Patients and Their Disease
According to Treatment Group
Characteristic
No. (%)
PTA
(n = 76)
Sham
(n = 39)
Female 45 (59) 29 (74)
Age, mean (SD), y 40.0 (10.3) 37.5 (10.6)
EDSS score
2 or 2.5 50 (66) 24 (62)
3 or 3.5 18 (24) 11 (28)
4 or 4.5 8 (11) 2 (5)
5 or 5.5 0 2 (5)
Median (interquartile range) 2.5 (2.0-3.0) 2.5 (2.0-3.5)
Mean (SD) 2.6 (0.7) 2.7 (0.9)
Years since MS diagnosis, median
(interquartile range)
4.3 (2.8-8.4) 6.1 (3.7-9.0)
Relapses in previous 2 years, No.
0 0 0
1 44 (58) 26 (67)
2 24 (32) 4 (10)
≥3 8 (11) 9 (23)
Median (interquartile range) 1.0 (1.0-2.0) 1.0 (1.0-2.0)
Mean (SD) 1.7 (1.2) 1.8 (1.4)
Intraluminal obstacle at ECD
in at least 1 IJV
Yes 74 (97) 37 (95)
No 2 (3) 2 (5)
Bidirectional and/or absent flow
at ECD in at least 1 IJV, in 2 positions
Yes 70 (92) 38 (97)
No 6 (8) 1 (3)
T1 gadolinium-enhancing lesions, No.
Median (range) 0 (0-8) 0 (0-3)
Mean (SD) 0.49 (1.2) 0.23 (0.58)
Immunomodulatory therapy
Yes 31 (41) 18 (46)
No 45 (59) 21 (54)
Abbreviations: ECD, color Doppler ultrasonography; EDSS, Expanded Disability
Status Scale; IJV, internal jugular vein; MS, multiple sclerosis; PTA, percutaneous
transluminal angioplasty.
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the functional end point—a difference of −7% (95% CI, −26.7
to 10.1) in favor of the sham group. The logistic model ad-
justed for sexanddiseasedurationprovidedanodds ratio (OR)
for improvement in the PTA group (compared with the sham
group) of 0.70 (95%CI, 0.31-1.59; P = .40). The OR for the un-
adjusted model was 0.75 (95% CI, 0.34-1.68; P = .49). Wors-
ening occurred in 9 patients (12%) in the PTAgroup vs 7 (19%)
in the sham group; functional stability was maintained in 17
(23%) in thePTAgroupand8 (22%) in theshamgroup.Amixed
outcome (improvement in one or more functions and wors-
ening in oneormore) occurred in 16patients (22%) in the PTA
group and 4 (11%) in the sham group. Results for individual
components of the functional end point are shown inTable 3.
More patients in the PTA group than in the sham group im-
proved in visual acuity andmanual dexterity, whilemore pa-
tients in the PTA group worsened for postvoid residual urine
volumeandbalance.Walking control remained stable inmost
patients of both groups.
The number of new lesions on MRI at 12 months com-
paredwith baselinewas unrelated to venous PTA; therewere
amean 1.40 new lesions in the PTA group vs 1.95 in the sham
group (mean ratio, 0.72; 95% CI, 0.32-1.63; P = .45; adjusted
P = .45) (Table 2). In the regression analysis adjusted for sex
and disease duration, the mean PTA-to-sham ratio was 0.50
(95%CI, 0.20-1.27;P = .30). Theproportionof patients free of
new lesions did not differ significantly between the PTA and
sham groups (63.0% vs 48.6%; OR, 1.80; 95% CI, 0.81-4.00;
P = .15; adjusted P = .30) (Table 2). At 12 months, 50 patients
(68%) in the PTA group were free of new or enlarged T2 le-
sionscomparedwith21 (57%) in theshamgroup (OR, 1.66;95%
CI,0.73-3.75;P = .22; adjustedP = .62), and53 (73%) in thePTA
groupwere freeof gadolinium-enhancing lesions at 12months
comparedwith 18 (49%) in the shamgroup (OR, 2.76; 95%CI,
1.14-6.68; P = .02; adjusted P = .08) (Table 4).
A post hoc analysis investigating new brain lesions at 0 to
6months (eTable1 inSupplement2)andat6to12monthsfound
that at 6 to 12months, 58of 70patients (83%) in thePTAgroup
and 22 of 33 (67%) in the sham group (OR, 2.64; 95% CI, 1.11-
6.28;P = .03; adjustedP = .09)were free of combinedbrain le-
sions,while therewere amean (SD) 0.36 (0.98) newT2 lesions
in thePTAgroupand 1.14 (2.63) in the shamgroup (P = .02; ad-
justedP = .06). Finally, 61 patients (87%) in the PTAgroup and
24(73%) in theshamgroup(OR,2.75;95%CI, 1.10-6.89;P = .03;
adjusted P = .09) were free of new T2 lesions (Table 4).
Secondary End Points
Eight of 115 patients with RRMS (7.0%) diagnosed as having
CCSVIbyECDhadnoabnormalitiesonvenography, so theposi-
tivepredictivevalueofECDwas93.0% inpatientswithRRMS.
The annualized relapse rate was 0.32 (95% CI, 0.2-0.4) in the
PTA group and 0.39 (95% CI, 0.2-0.5) in the sham group, giv-
ing a relative rate of 0.82 (95%CI, 0.40-1.71;P = .60). Theme-
dian (interquartile range) baseline EDSS score was 2.5 (2.0-
3.0) in the PTA group and 2.5 (2.0-3.5) in the sham group
(Table 1). At 12months, themedian (interquartile range) EDSS
scorewas 2.0 (1.5-3.0) in thePTAgroupand2.0 (1.5-2.5) in the
shamgroup (P = .49). Seventeenof73patients (23%) in thePTA
group had least 1 relapse over the 12 months compared with
12 of 39 (31%) in the sham group. Blinded flow assessment at
12months revealed restored flow in 38 of 71 patients (54%) in
the PTA group and 14 of 37 (38%) in the sham group.
Secondary ProgressiveMS
Primaryendpoints for the 15patientswith secondaryprogres-
sive MS (10 in the PTA group and 5 in the sham group) are
shown, in descriptive formonly, in eTable 2 in Supplement 2.
Discussion
Venous PTA did not increase the proportion of patients with
RRMS who improved on the functional composite measure
compared with the sham procedure over the 12-month
follow-up, nor did it significantly reduce the appearance of
new combined brain lesions on MRI at 0 to 12 months.
Expanded Disability Status Scale disability measures were
Table 2. Results for Components of Composite Functional End Point andMagnetic Resonance Imaging (MRI) End Point
Finding
No. (%) Unadjusted Estimated
Effect of Venous PTA,
OR (95% CI) P Value
Adjusted
P Valuea
PTA
(n = 73)
Sham
(n = 37)
Composite functional end pointb
Improved 30 (42) 18 (49) 0.75 (0.34-1.68)c
.49 NA
Stable 17 (24) 8 (22) NA
Worsened 9 (13) 7 (19) NA
Mixed 16 (22) 4 (11) NA
MRI end point (new combined lesions)d
No. of lesions, mean (SD) 1.40 (4.21) 1.95 (3.73) 0.72 (0.32-1.63)e .45 .45
Median (range) 0 (0-31) 1 (0-8) NA NA NA
No. patients free of new lesions 46 (63) 18 (49) 1.80 (0.81-4.01)f .15 .30
Abbreviations: NA, not applicable; OR, odds ratio; PTA, percutaneous
transluminal angioplasty.
a P values adjusted for multiplicity with Hommel method.17
b Seventy-two patients in the PTA group had composite functional end point
data.
c OR for PTA group improvement with 95% CI and P value from logistic model.
dNew combined lesions include new lesions on T2-weighted images,
preexisting lesions enlarged by >30% on T2-weighted images, and
gadolinium-enhancing lesions in T1-weighted images of preexisting lesions
(no enlarged T2 lesions were observed).
e Mean lesion ratio with 95% CI and P value from negative-binomial model.
f OR of being lesion free with 95% CI and P value from χ2 test.
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stable and similar between the groups at 12 months, match-
ing the composite functional outcome. The annualized
relapse rate was also similar between the groups. Safety data
indicated no serious adverse events attributable to venous
PTA or the sham procedure.
The functional outcome explored by the trial was reduc-
tion in disability as assessed by 5 functions (ie, walking con-
trol, balance, manual dexterity, postvoid residual urine vol-
ume, andvisual acuity; eMethods in Supplement 2),which are
themost frequentcausesofdisability inMS.Thehypothesis that
venousPTAcansignificantlyreducedisability isrejectedbyfind-
ings from this study, which not only found no difference be-
tweenthegroupsonthe functional compositemeasurebutalso
no difference for any of its 5 components (Table 3).
TheprimaryMRIoutcomemeasurewasadifference in the
number of new combined brain lesions. Venous PTA had no
effect on thismeasure (Table 2).However, at 12months,more
than20%ofpatients in thePTAgroupwere freeofgadolinium-
enhancing lesions compared with the sham group (OR, 2.76;
95% CI, 1.14-6.68) (Table 4). To explore this effect, which ap-
pears inconsistent with the otherMRI data at 0 to 12months,
weperformedanexploratoryposthoccomparisonofMRI find-
ings at 0 to 6 months with those at 6 to 12 months (Table 4;
eTable 1 in Supplement 2). We found a reduction in themean
number of new brain lesions (corresponding to more lesion-
freepatients) in thePTAgroupcomparedwith the shamgroup
at 6 to 12months. Thedelayed andpositive effect on themag-
netic resonance biomarker suggests that PTA could affect the
dynamic of the blood-brain barrier.
Gadolinium enhancement is a marker of damage to the
blood-brain barrier, whose time course depends on lym-
phatic drainage18 and hence on venous drainage from the
skull.19 Previous studies have reported that venous pressure
is lowered3 and cerebrospinal fluid dynamics is improved20
after venous PTA, thereby favoring the drainage of cerebro-
spinal fluid into the dural veins,which depends on a pressure
gradientbetweenthesubarachnoidspacesandduralveins.21,22
Another study23 reported that white matter lesion load was
Table 3. Detailed Results for Components of Primary Functional End Pointa
Functional
Assessment
Total
No.
At 12 mo, No. (%) Baseline Score Score at 12 mo
Improved Stable Worsened Median (Range) Mean (SD) Median (Range) Mean (SD)
Visual Acuity (No. of Lines Read)
100% Contrast
PTA 72 5 (7) 64 (89) 3 (8) 12.0 (8.0-14.0) 11.9 (1.0) 12.0 (9.0-14.0) 11.9 (1.0)
Sham 37 1 (3) 33 (89) 3 (4) 12.0 (6.0-14.0) 11.9 (1.6) 12.0 (6.0-14.0) 11.6 (1.7)
2.5% Contrast
PTA 72 6 (8) 61 (85) 5 (7) 8.0 (3.0-10.0) 7.5 (1.3) 8.0 (5.0-10.0) 7.64 (1.2)
Sham 37 1 (3) 33 (89) 3 (8) 8.0 (3.0-10.0) 7.3 (1.7) 8.0 (1.0-10.0) 7.22 (1.9)
1.25% Contrast
PTA 72 11 (15) 59 (82) 2 (3) 6 (1.0-8.0) 5.7 (1.4) 6.0 (3.0-9.0) 6.00 (1.5)
Sham 37 4 (11) 30 (81) 3 (8) 6 (0.0-8.0) 5.3 (2.0) 5.0 (0.0-10.0) 5.41 (2.3)
Any contrast
PTA 72 15 (21) 49 (68) 8 (11) NA NA NA NA
Sham 37 5 (14) 27 (73) 5 (14) NA NA NA NA
Manual Dexterity (No. of Cubes Displaced)
Dominant hand
PTA 72 13 (18) 55 (76) 4 (6) 67.3 (38.0-81.0) 64.5 (10.1) 68.3 (40.5-89.5) 67.7 (10.1)
Sham 37 5 (14) 31 (84) 1 (3) 66.0 (36.0-85.5) 64.4 (11.4) 67.0 (42.0-92.5) 67.0 (13.1)
Nondominant hand
PTA 72 14 (19) 55 (76) 3 (4) 63.5 (35.0-77.0) 61.6 (9.3) 64.8 (31.5-83.0) 64.4 (11.3)
Sham 37 6 (16) 30 (81) 1 (3) 61.0 (42.5-86.0) 62.4 (10.9) 63.0 (38.0-89.0) 64.8 (12.8)
Any hand
PTA 72 18 (25) 50 (69) 4 (6) NA NA NA NA
Sham 37 7 (19) 29 (78) 1 (3) NA NA NA NA
Postvoid Residual Urine Volume (mL)
PTA 69 20 (30) 36 (54) 11 (16) 43.0 (0.0-256.0) 64.7 (61.4) 33.0 (0.0-327.0) 50.3 (58.9)
Sham 36 11 (31) 22 (61) 3 (8) 54.0 (0.0-263.0) 73.2 (69.1) 35.5 (0.0-277.0) 57.3 (64.4)
Balance Test (% Adherence to Path)
PTA 72 16 (22) 51 (71) 5 (7) 84.0 (46.0-109.0) 82.5 (12.0) 88.5 (54.0-102.0) 85.0 (10.2)
Sham 37 8 (22) 28 (76) 1 (3) 81.0 (60.0-99.0) 78.6 (11.7) 84.0 (60.0-102.0) 82.2 (11.8)
Walking Control (Walk Ratiob)
PTA 72 0 70 (97) 2 (3) 5.5 (4.2-7.6) 5.6 (0.8) 5.5 (4.2-7.5) 5.6 (0.8)
Sham 37 0 36 (97) 1 (3) 5.4 (3.7-7.3) 5.3 (0.8) 5.3 (3.6-7.1) 5.3 (0.8)
Abbreviations: NA, not applicable; PTA, percutaneous transluminal angioplasty.
a All P values were >.99 after adjustment for multiplicity.
b Ratio of step length (millimeters) to step frequency (per minute).
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inversely correlatedwith reduced cerebrospinal fluiddynam-
ics, as measured by MRI. In addition, flow improvement
through the internal jugular veins owing to venous PTA has
been reported to improve brain perfusion in patients with
RRMS.21 It has also been reported that the development of a
newMS plaque was preceded by sustainedMRI-detected hy-
poperfusion before the plaque was identified on MRI.24,25
To our knowledge, few published data are available to
compare with Brave Dreams findings. The positive effect of
venous PTA on disability found in the first open-label pilot
study3 was not confirmed in the present study. The first
study3 was not blinded and used the MSFC and the EDSS
scores as primary end points. There is some degree of sub-
jectivity in assessing MSFC and EDSS scores, and with non-
blinded patients and outcome assessors, detection bias may
have been introduced.
In a sham-controlled randomized trial,26 19 patientswith
MS (9 assigned to PTA and 10 to sham)were assessed 1, 3, and
6months after intervention. Itwas found that clinical andMRI
end points were closely similar in the 2 groups. However, the
study was flawed by the small number of recruited patients
and short follow-up.26 In an observational study,27 29 pa-
tientswithRRMSwere observed for 2 years after venous PTA.
A small improvement in mean EDSS score occurred over that
time, and the mean annual relapse rate also lowered. Mag-
netic resonance imaging data were not reported.
Limitations
Our studyhas several limitations.Despite being, toourknowl-
edge, the largest randomized study on venous PTA in RRMS,
the power of the study was limited. There are at least 3 main
reasons for this. First, many MS centers are reluctant to pro-
pose patients for a trial exploring a controversial hypothesis.
Thus, of the 15 centers that initially joined the trial, only 6 ac-
tively recruited. Second, many patients are reluctant to par-
ticipate in a randomized sham-controlled study in spite of the
fact that randomizationwas2:1 in favor of angioplasty; this re-
luctancemayhavebeenexacerbatedby themedia,whichover-
emphasized the effectiveness of venous PTA. Third, the sud-
den widespread availability of venous PTA (and stenting) in
private centers decreased thenumber of patients fulfilling the
inclusioncriterionofnopreviousangioplasty.Aposthocpower
calculation, based on control findings, indicated a power of
30%todetect adifference in the functional endpoint and 17%
power to detect the target difference in theMRI end point. In
terms of effect size and clinical relevance, the 95% CI for the
estimated 7% advantage of sham varied from 26.7% in favor
of sham to 10.1% in favor of PTA, thereby excluding the 15%
target threshold for a benefit of venous PTAon the functional
end point. However, the findings on new MRI lesions do not
completely exclude an effect of venous PTA, since the 95%CI
for the mean lesion ratio of 0.72 in favor of PTA includes the
0.65 target for PTA improvement (95% CI, 0.32-1.63).
The use of a new composite functional outcomemeasure
was a major challenge. Although the outcomes and change
thresholds (reflecting sensitivity to change) of the individual
componentshavebeenvalidated (eMethods inSupplement2),
the composite is presented for the first time in this article.
Another limitationof the trial is that the severityof theen-
rolledpatients in termsofEDSSscoreand lesion loadwas lower
Table 4. Magnetic Resonance Imaging Findings at 6 to 12Months and 0 to 12Months
Measure
Months 6-12 Months 0-12
PTA
(n = 70)
Sham
(n = 33) P Value
Adjusted
P Valuea
PTA
(n = 73)
Sham
(n = 37) P Value
Adjusted
P Valuea
New combined brain lesionsb
No. of lesions, mean (SD) 0.47 (1.19) 1.27 (2.65) NA NA 1.40 (4.21) 1.95 (3.73) NA NA
Mean lesion ratio (95% CI)c 0.37 (0.15-0.91) .03 .09 0.72 (0.32-1.63) .45 .45
Median (range) 0 (0-7) 0 (0-13) NA NA 0 (0-31) 1 (0-8) NA NA
Patients free of lesions, No. (%) 58 (79.5) 22 (59.5) NA NA 46 (63.0) 18 (48.7) NA NA
Lesion free, OR (95% CI)d 2.64 (1.11-6.28) .03 .09 1.80 (0.81-4.01) .15 .30
New or enlarged T2 lesions
No. of lesions, mean (SD) 0.36 (0.98) 1.14 (2.63) NA NA 1.10 (3.03) 1.59(3.42) NA NA
Mean lesion ratio (95% CI)c 0.31 (0.11-0.86) .02 .06 0.69 (0.28-1.67) .41 .82
Median (range) 0 (0-5) 0 (0-13) NA NA 0 0 (0-18) NA NA
Patients free of lesions, No. (%) 61 (83.6) 24 (64.9) NA NA 50 (68.5) 21 (56.8) NA NA
Lesion free, OR (95% CI)d 2.75 (1.10-6.89) .03 .09 1.66 (0.73-3.75) .22 .62
Gadolinium-enhancing T1 lesions
No. of lesions, mean (SD) 0.36 (1.08) 0.59 (1.55) NA NA 1.07 (4.11) 1.06 (2.47) NA NA
Mean lesion ratio (95% CI)c 0.60 (0.20-1.75) .35 .35 1.01 (0.35-2.93) .98 .98
Median (range) 0 (0-7) 0 (0-9) NA NA 0 0 (0-14) NA NA
Patients free of lesions, No. (%) 62 (84.9) 26 (70.3) NA NA 53 (76.8) 18 (54.6) NA NA
Lesion free, OR (95% CI)d 2.38 (0.92-6.19) .07 .14 2.76 (1.14-6.68) .02 .08
Abbreviations: NA, not applicable; OR, odds ratio; PTA, percutaneous
transluminal angioplasty.
a P values adjusted for multiplicity using Hommel method.17
bNew combined lesions included new lesions on T2-weighted images,
preexisting lesions enlarged by >30% on T2-weighted images, and
gadolinium-enhancing lesions in T1-weighted images of preexisting lesions (no
enlarged T2 lesions were observed).
c Estimated effect of PTA on number of lesions; negative-binomial model was
used to derive P values.
d Estimated effect of PTA on proportion lesion-free patients; χ2 test was used to
derive P values.
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than anticipated, and patients with active disease may have
beenunderrepresented in the study (Table 1). Finally, the fact
that venousPTAwas largely ineffective in restoringblood flow
innearlyhalf thepatients in thePTAgroupsuggests that itwas
inadequate for exploring our initial hypothesis.
Conclusions
A number of neurologists and scientists expressed the opin-
ion that the decision to conduct a trial on CCSVI in the
absence of valid scientific evidence was unethical and a
waste of resources.28 However, we believe that the best way
to provide useful information to patients (and regulatory
authorities) on the benefit and safety of venous PTA was to
conduct a randomized trial—as also recommended by
NICE7—that assessed outcomes directly relevant to
patients.29 Venous PTA has proven to be a safe but ineffec-
tive technique in treating CCSVI in about half of patients.
The procedure cannot be recommended for treatment of
patients with MS; no further double-blinded clinical studies
are needed. The delayed effect of venous PTA 6months after
the procedure on the magnetic resonance biomarker sug-
gests a possibility that PTA may produce benefit for a sub-
group of patients with MS. This should be further analyzed
and investigated.
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